10x Genomics
365 hedge funds and large institutions have $11.9B invested in 10x Genomics in 2021 Q4 according to their latest regulatory filings, with 87 funds opening new positions, 121 increasing their positions, 109 reducing their positions, and 46 closing their positions.
89% more first-time investments, than exits
New positions opened: 87 | Existing positions closed: 46
13% more funds holding in top 10
Funds holding in top 10: 8 → 9 (+1)
11% more repeat investments, than reductions
Existing positions increased: 121 | Existing positions reduced: 109
11% more funds holding
Funds holding: 330 → 365 (+35)
4% more capital invested
Capital invested by funds: $11.5B → $11.9B (+$410M)
0.36% more ownership
Funds ownership: 86.97% → 87.32% (+0.36%)
20% less call options, than puts
Call options by funds: $29.7M | Put options by funds: $37M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sands Capital Management
Arlington,
Virginia
|
+$255M |
| 2 |
DCP
D1 Capital Partners
New York
|
+$246M |
| 3 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$205M |
| 4 |
ClearBridge Investments
New York
|
+$114M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
+$79.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$186M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$180M |
| 3 |
Wells Fargo
San Francisco,
California
|
-$91.6M |
| 4 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$77.4M |
| 5 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$67.6M |
TXG Hedge Fund Activity: Q4 2021 in Review
365 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in 10x Genomics (TXG) for Q4 2021, worth a combined $11.9B — up 3.6% from $11.5B a quarter earlier.
Buyers outnumbered sellers: 87 funds opened new TXG positions and 46 closed out — a net gain of 41 holders — while 121 added to existing stakes and 109 trimmed.
The largest buyer was Sands Capital Management, opening a new position worth an estimated $255M. The largest seller was Morgan Stanley, cutting an estimated $186M.
- 365 institutional investors held 10x Genomics (TXG) as of Q4 2021, up from 330 in Q3 2021.
- Funds reported $11.9B of 10x Genomics stock for Q4 2021, up 3.6% quarter-over-quarter.
- 87 funds opened new 10x Genomics positions in Q4 2021 and 46 closed out, a net change of +41 holders.
- The largest 10x Genomics buyer in Q4 2021 was Sands Capital Management, an estimated $255M added.
- The largest 10x Genomics seller in Q4 2021 was Morgan Stanley, an estimated $186M sold.
Based on aggregated 13F filings for Q4 2021.